Funding for this research was provided by:
sandoz biopharmaceuticals/hexal ag
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Received: 6 August 2021
Accepted: 27 February 2022
First Online: 14 March 2022
: JH, MDD, NM, NK, AK and RN are employees of Sandoz-Hexal, sponsor of the trial and manufacturer of filgrastim “Zarzio”. HB has received research funding and served on the speaker’s board of Sandoz-Hexal. The other authors have no declarations.